• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, May 13, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Cheap but desirable: Generic drugs a great alternative to the brand-names for hypertension

Bioengineer by Bioengineer
May 4, 2021
in Science News
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

For hypertension, generic drugs could be as good an option as brand-name drugs while costing only half as much, study suggests

IMAGE

Credit: Chinese Medical Journal

Hypertension is a common medical condition and a primary cause of cardiovascular diseases and stroke worldwide. Unfortunately, as Professor Wei-Li Zhang of the Chinese National Center for Cardiovascular Diseases notes, “the unaffordability of drugs is a major barrier to medication adherence among patients living in low- and middle-income areas.”

One of the countries where hypertension is becoming a major problem is China where, researchers estimate, between 244 million and 300 million adults are living with hypertension. But true to Prof. Zhang’s words, most cases of hypertension in China are not adequately controlled, and patients who do seek treatment for hypertension must pay for outpatient clinic visits and bear medication costs out-of-pocket.

An emerging option for controlling the costs of antihypertensive pharmacotherapy is to prescribe generic drugs, which have the same active ingredients as their brand-name counterparts but cost substantially less. Several countries have taken steps to encourage the prescription of generic drugs as a way of reducing healthcare spending and enabling more patients, but some clinicians have reservations about prescribing generics due to concerns that such drugs may not be as effective as their brand-name counterparts. A team of researchers led by Prof. Zhang therefore decided to conduct an investigation to determine whether generic antihypertensive drugs are as effective as brand-name drugs at controlling blood pressure over the long term. Their results appear in a paper recently published in Chinese Medical Journal.

In their study, they analyzed data from a cohort study of patients with hypertension conducted across 18 hospitals in 12 Chinese provinces. Baseline screenings occurred between 2013 and 2015, and follow-up assessments continued until August 1, 2017. The researchers focused on 2,176 study participants who used brand-name antihypertensive drugs and 4,352 participants who used generic drugs. They conducted statistical analyses to compare the two groups in terms of changes in blood pressure over the follow-up period.

They found that generic drugs were just as effective as brand-name drugs at lowering blood pressure. Between the group using generic drugs and that using brand-name drugs, the percentages of patients who achieved well-controlled blood pressure levels (defined here as systolic blood pressures below 140 mmHg and diastolic blood pressures below 90 mmHg) and the likelihoods of experiencing adverse cardiovascular outcomes, such as coronary heart disease and stroke, were similar. After adjusting for age, sex, body mass index values, the number of antihypertensive drugs taken, and traditional cardiovascular risk factors, the mean reduction in systolic blood pressure was 7.9 mmHg for participants who took brand-name drugs and 7.1 mmHg for participants who took generic drugs.

However, some differences in outcomes did emerge when the researchers examined specific participant subgroups. Among participants who were younger than 60 years old, those who took brand-name drugs were more likely to achieve well-controlled blood pressure levels than their counterparts who took generic drugs were. A similar difference between brand-name drugs and generic drugs emerged when the investigators restricted their analyses to men with hypertension.

Despite the differences observed in the subgroup analyses, the results provide strong evidence overall for generic drugs being just as effective as brand-name ones at lowering blood pressure levels. Importantly, the generic drugs achieve these effects at a much lower cost; a 1-mmHg reduction in systolic blood pressure turned out to be US$315.40 cheaper with generic drugs than with brand-name ones. This cost difference means that treatment with generic drugs is only half as expensive as treatment with brand-name drugs, and this will doubtless mean a great deal to the many people in China and beyond who live on low-to-medium incomes.

That’s why Prof. Zhang expresses hope that these findings will provide “an impetus for physicians and patients to preferentially use generic drugs instead of expensive brand-name drugs to lower blood pressure levels.” By expanding access to antihypertensive treatment, the use of generic drugs will provide important benefits to public health within China and other developing countries.

###

Reference

Titles of original papers: Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China

Journal: Chinese Medical Journal

DOI: 10.1097/CM9.0000000000001360

Media Contact
Peifang Wei
[email protected]

Related Journal Article

http://dx.doi.org/10.1097/CM9.0000000000001360

Tags: BiologyBiomedical/Environmental/Chemical EngineeringCardiologyGeneticsMedicine/HealthPhysiologyStroke
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Boosting Optical Nonlinearities in Plasmonic Nanostructures

May 13, 2025
blank

Measuring Quality of Life Post-Transplant Vital

May 13, 2025

Primate Brain Stress Hormone Pathways Uncover Crucial Clues for Advancing Human Mental Health Research

May 13, 2025

Improved IVF Success Rates Achieved with Simple Oral Swab Test

May 13, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Volatile-Rich Cap Found Above Yellowstone Magma

    665 shares
    Share 266 Tweet 166
  • Natural Supplement Shows Potential to Slow Biological Aging and Enhance Muscle Strength

    88 shares
    Share 35 Tweet 22
  • The Rise of Eukaryotic Cells: An Evolutionary Algorithm Spurs a Major Biological Transition

    67 shares
    Share 27 Tweet 17
  • Analysis of Research Grant Terminations at the National Institutes of Health

    66 shares
    Share 26 Tweet 17

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Optical Nonlinearities in Plasmonic Nanostructures

Measuring Quality of Life Post-Transplant Vital

Primate Brain Stress Hormone Pathways Uncover Crucial Clues for Advancing Human Mental Health Research

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.